Amgen is executing well as six growth drivers offset patent losses, but heavy leverage and a rich valuation keep the stock in Hold territory.
Amgen (AMGN) combines strong commercial execution, a broad biologics portfolio, and a deep late-stage pipeline with a balance sheet that remains heavily leveraged. The core investment case rests on the shift from mature products toward six growth drivers that expanded 26% year over year in Q2 2026 and represented nearly 70% of product sales. Repatha, EVENITY, TEZSPIRE, rare disease medicines, innovative oncology products, and biosimilars are carrying the business through patent losses.
Q2 2026 revenue reached $10.1B, up 10% year over year, while non-GAAP EPS rose to $6.29 from $6.02 and exceeded the $5.62 consensus estimate. Management raised 2026 non-GAAP EPS guidance to $22.30-$23.50 and revenue guidance to $38.2B-$39.4B. Those figures support a constructive operating view, but the stock price of $442.24 already sits near the $447.03 52-week high, while the analyst consensus target is $388.03.
The appropriate stance for a moderate-risk, medium-term investor is Hold. Amgen offers durable cash generation, a 5.8% free-cash-flow yield, and meaningful pipeline optionality. The counterweight is $54.6B of debt at year-end 2025, a 1.1 current ratio, and a PEG ratio of 2.3. The business is executing well, but the share price leaves limited room for operational disappointment.
Amgen is a global human therapeutics company founded in 1980 and listed on NASDAQ under AMGN. It employed approximately 31,500 people and generated $36.7B of revenue in 2025. Robert A. Bradway serves as chairman and chief executive officer. The company operates as one human therapeutics business spanning cardiovascular medicine, inflammation, oncology, bone health, rare disease, and biosimilars.
The portfolio includes Repatha, Prolia, XGEVA, EVENITY, Otezla, Enbrel, TEZSPIRE, TEPEZZA, UPLIZNA, BLINCYTO, IMDELLTRA, Nplate, Vectibix, KYPROLIS, KRYSTEXXA, Aranesp, and biosimilar products. This breadth reduces reliance on a single medicine, although the portfolio contains both fast-growing launches and mature assets facing biosimilar or generic competition.
Amgen's business model combines drug discovery, clinical development, global commercialization, and large-scale biologics manufacturing. The model also includes lifecycle management through new indications, geographic expansion, dosing improvements, and payer-access work. That combination gives Amgen more control over supply and commercialization than a research-only biotechnology company.
Amgen reports one human therapeutics segment, but its Q2 2026 materials divide performance into General Medicine, Rare Disease, Inflammation, Oncology, and Established Products. The mix is moving toward newer growth franchises. Six drivers grew 26% year over year, and 22 products delivered double-digit sales growth during the quarter.
General Medicine produced strong momentum from Repatha and EVENITY. Repatha sales were $953M, up 37%, while EVENITY sales reached $714M, up 38%. The offset came from Prolia and XGEVA, which generated combined sales of $1.1B, down 33% because several biosimilar competitors had launched.
Rare Disease and Inflammation are providing a second layer of growth. UPLIZNA sales rose 90% to $335M, TEZSPIRE increased 42% to $486M, and TEPEZZA grew 14% to $576M. In Oncology, IMDELLTRA sales increased 115% to $288M and BLINCYTO advanced 23% to $472M. Biosimilars added $855M of Q2 sales, up 29%.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Repatha is Amgen's clearest flagship growth product. It generated $3.0B of 2025 sales, up 36%, and reached $953M in Q2 2026. U.S. new-to-brand prescriptions grew more than 50% year over year, giving the product both volume momentum and a larger treatment base.
The product's strategic advantage is supported by outcomes data. Amgen said Repatha is the only PCSK9 inhibitor with Phase 3 outcomes data in both primary and secondary prevention. In VESALIUS-CV, Repatha reduced three-point major adverse cardiovascular events by 29% in high-risk diabetes patients with and without atherosclerosis, alongside a nominal 21% reduction in all-cause death.
Prolia and XGEVA show the other side of the portfolio. Their combined Q2 sales fell 33% after biosimilar launches, while Prolia represented 12.5% of 2025 revenue and XGEVA represented 5.9%. Repatha's expansion is important because it helps replace revenue exposed to exclusivity losses.
Amgen's strongest competitive advantage is the combination of biologics expertise, clinical scale, commercial reach, and manufacturing capacity. The company has generated more than $15B of biosimilar sales since its first approvals in 2018, giving it experience competing both as an innovator and as a lower-cost supplier.
The pipeline adds meaningful optionality. MariTide is in Phase 3 development across obesity and related chronic diseases, Olpasiran is advancing in two Phase 3 outcome studies targeting Lp(a), and Xaluritamig is in two Phase 3 studies for metastatic castration-resistant prostate cancer. UPLIZNA is also expanding across autoimmune conditions after showing an 87% reduction in flare risk versus placebo during the first year of the MITIGATE study.
Innovation spending is rising alongside the pipeline. Q2 non-GAAP R&D expense increased 10% year over year. Amgen is also applying artificial intelligence, proprietary data, and high-performance computing across discovery, development, manufacturing, and access. AMG 513 was discontinued, which shows that management is pruning lower-priority programs while concentrating resources on larger opportunities.
Amgen's manufacturing footprint is a major part of its moat. Management highlighted biologics production at scale and is investing across facilities in North Carolina, Ohio, and Puerto Rico. Q2 capital expenditures were $500M, and full-year 2026 capital expenditures are expected to reach approximately $2.6B, including capacity for potential MariTide volume.
The supply-chain investment is supported by cash generation. Q2 operating cash flow was $4.0B and free cash flow was $3.49B. Annual 2025 operating cash flow was $10.0B, while annual free cash flow was $8.1B. Those figures provide internal funding for manufacturing expansion, clinical trials, dividends, and selective business development.
The biosimilar operation demonstrates the commercial value of this infrastructure. PAVBLU sales reached $287M in Q2, up 121%, with Amgen emphasizing its ready-to-use prefilled syringe and reliable biologics supply. Scale improves the economics of production, but the same manufacturing network also requires substantial capital spending as the product mix evolves.
Amgen is positioned in several large treatment markets with clear evidence of underpenetration. Management estimates that approximately 100 million patients worldwide remain above their LDL-C goals, while more than 1 million U.S. patients currently use Repatha. EVENITY has reached only mid-single-digit penetration among approximately 2 million U.S. women at very high fracture risk.
Obesity is the largest pipeline opportunity, but it is also one of the most competitive areas in biopharma. Industry research cited more than 100 obesity compounds in development, including more than 35 with a GLP-1 component. MariTide's monthly or less-frequent dosing design gives Amgen a distinct product thesis, while Phase 3 execution remains central to converting that thesis into commercial value.
Oncology and autoimmune disease provide additional market depth. IMDELLTRA is being tested in earlier lines of small-cell lung cancer, with management identifying as many as 28,000 addressable U.S. patients in earlier treatment settings. TEZSPIRE is expanding beyond severe asthma into chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Amgen sells through a healthcare delivery system that includes physicians and their clinics, hospitals, dialysis centers, pharmacies, and pharmaceutical wholesalers. The commercial decision often involves more than a physician's prescription. Payer coverage, patient support, site of care, dosing convenience, and supply reliability all influence adoption.
Access expansion is visible across the portfolio. TEZSPIRE has gained expanded Medicare access, including self-administration coverage. UPLIZNA benefits from broad payer coverage and twice-yearly maintenance dosing. TEPEZZA has reached more than 25,000 U.S. patients and is launched in 13 countries, with six additional countries planned.
International adoption adds another demand channel. EVENITY holds more than 55% volume share in Japan, where 1 million patients have been treated. BLINCYTO sales outside the U.S. grew 64% in Q2, led by Europe and Japan. These figures show how geographic expansion can offset pressure in mature U.S. franchises.
Competition is product-specific. Repatha competes with Novartis' Leqvio and Regeneron and Sanofi's Praluent. Otezla competes with products from AbbVie, Eli Lilly, Johnson & Johnson, and Novartis. Prolia and XGEVA face bisphosphonates, generics, and denosumab biosimilars.
Amgen's scale is a competitive strength in biologics, but it does not eliminate price pressure. The company competes with AbbVie, Eli Lilly, Johnson & Johnson, Novartis, Roche, Pfizer, Sanofi, Bristol Myers Squibb, Merck, and Gilead across overlapping therapeutic categories. Large rivals possess substantial clinical, regulatory, manufacturing, and commercial resources.
The portfolio's mix determines competitive durability. Repatha benefits from clinical outcomes data, UPLIZNA from a differentiated CD19 mechanism and twice-yearly dosing, and the biosimilar business from manufacturing scale. Conversely, mature products such as Prolia, XGEVA, Otezla, and KYPROLIS face direct pressure from biosimilars, generics, or newer branded therapies.
Drug pricing policy is the most direct macro factor for Amgen. Medicare price-setting provisions under the Inflation Reduction Act began in 2026, while Amgen's annual reporting identifies payer scrutiny, rebate pressure, reimbursement policy, and government pricing actions as risks to sales and margins.
The regulatory environment also cuts both ways. The FDA took steps in March 2026 to streamline biosimilar development, which can improve biologic access but also accelerate competition against mature Amgen products. Amgen's own biosimilar portfolio gives it a partial hedge because the company can capture revenue as both a branded supplier and a lower-cost entrant.
Amgen's global footprint creates exposure to international regulation and supply-chain execution. The company is expanding TEPEZZA across additional countries, received a positive European opinion for a broader Repatha label, and has manufacturing investment in Puerto Rico alongside U.S. facilities. Those facts support geographic diversification, while the breadth of operations increases the importance of regulatory and production discipline.
Amgen carries $54.6B of debt and a 1.1 current ratio, leaving leverage as the main constraint on an otherwise durable cash-generating business.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue rose 10% to $10.1B and non-GAAP EPS climbed to $6.29, topping consensus by a wide margin.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 non-GAAP EPS guidance to $22.30-$23.50 and revenue guidance to $38.2B-$39.4B after a strong second quarter.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $442.24, the stock trades above our $400 fair value and near its $447.03 52-week high, while the PEG ratio sits at 2.3.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The analyst consensus target is $388.03, below the current share price and our $400 fair value, reinforcing a Hold stance.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Amgen has moved from a patent-expiration story toward a portfolio-renewal story. Q2 2026 showed the strategy working: revenue grew 10%, six growth drivers expanded 26%, and management raised full-year guidance. Repatha, UPLIZNA, TEZSPIRE, IMDELLTRA, biosimilars, and MariTide give the company several avenues for continued expansion.
The investment is not without friction. Debt remains high, the current ratio is only 1.1, and Prolia and XGEVA are declining under biosimilar pressure. With the stock near its 52-week high and above the analyst consensus target, execution is already reflected in the price. A Hold rating captures a strong operating business whose medium-term upside is real but whose margin of safety is currently limited.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Amgen Inc. (AMGN) drops sharply after BMO Capital cut its rating from Outperform to Market Perform. The move comes despite solid earnings momentum, with investors weighing valuation, biosimilar pressure, and growth from Repatha and Tezspire.
Amgen Inc. (AMGN) rises after reporting a Q2 earnings beat and raising its full-year outlook. Strong sales growth in key products, improved cash flow, and fresh analyst target hikes helped push the stock above its 52-week high.
Amgen’s portfolio is shifting toward faster-growing products like Repatha, EVENITY, and TEZSPIRE, but leverage and biosimilar erosion keep the stock in Hold territory. MariTide is the key medium-term catalyst, while Prolia and XGEVA remain the biggest drag.